Xyphos

Xyphos is committed to developing a flexible and controllable CAR-T cell therapy, offering potential cancer treatment options for patients. Our ACCEL technology enables precise control of CAR-T cells based on any tumor-specific antibody, providing a therapeutic platform that: enhances CAR-T safety and accesses new target spaces, prevents tumor recurrence by enabling target switching or multiplexing, and broadens potential indications through the deployment of convertible CAR-T therapeutics.Backed by a robust portfolio of issued and pending patents, Xyphos is merging cell therapy and antibody therapy to achieve safety, efficacy, and versatility, ultimately bringing promising therapies to cancer patients.